CliffBio
small molecule

LEVETIRACETAM IN SODIUM CHLORIDE

LEVETIRACETAM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameLEVETIRACETAM IN SODIUM CHLORIDE
Active ingredientLEVETIRACETAM
Strength1.5GM/100ML (15MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.